HI
LO
PRO
High
Concentration
+
Low
Viscosity
Protein Biologics
The HILOPRO® technology uses patented platform technology with GRAS excipients to enable innovator mAbs and biosimilars for SubQ delivery, optimized dosing and enhanced market acceptance.
This single formulation technology works for a wide range of monoclonal antibodies, supports multiple dosing and delivery options providing greater flexibility and optimal patient convenience.
HILOPRO
®
High concentration formulation offers extended release, resulting in long acting protein formulations.
Reduces the frequency of injections.
Low viscosity formulation enables the change of administration from Intravenous (IV) to Subcutaneous (SubQ).
Facilitates the delivery using syringes, autoinjector devices or pens.
Dose
(Fixed or variable)
Formulation (Concentration
and viscosity)
Devices
(Type of device
and volume)
Delivery
(High concentration - Low volume IV or SubQ)
Qprotyn's
IV to SubQ
System Approach
The HILOPRO® platform technology enables SubQ delivery of mAbs by formulating,
a high-concentration, low-viscosity, low-volume solution and combining it with an appropriate delivery device like syringe, a wearable device or an auto-injector.
This system approach provides the most convenient and cost effective method of converting IV formulations into SubQ.
100% of the mAbs tested have shown
a dramatic reduction in viscosity
In May 2020, Bhami’s Research Laboratory (BRL) was granted a US patent for an elegant new technology for High Concentration Formulations with Reduced Viscosity.
Qprotyn represents BRL and is the distributor of BRL’s patented viscosity reduction technology.
